What is the research dosage of MK-677?

The human research on ibutamoren converged on roughly 25 mg once daily by mouth, a dose that raised 24-hour growth-hormone and IGF-1 concentrations in the studies. It was used as a flat daily dose rather than a stepped titration. These figures are reproduced as a laboratory research reference only and are not a human dosing protocol or medical advice.

What is MK-677's half-life?

MK-677's elimination half-life is reported at approximately 24 hours. That long duration of action is what allows a single daily dose to sustain elevated growth-hormone pulses, and it is the main pharmacokinetic difference from the injectable peptide secretagogues, whose half-lives are minutes to a couple of hours.

No. Despite being grouped with 'peptides' in the research-compound community, MK-677 is an orally active small molecule that acts at the ghrelin receptor — it has no amino-acid sequence. That is why it is dosed orally instead of injected and why its certificate of analysis has to confirm small-molecule identity and purity rather than a peptide sequence.

Does Titan sell MK-677?

No. Titan does not stock MK-677. If the interest is the growth-hormone axis, the compound Titan supplies is the injectable CJC-1295 + Ipamorelin blend, a genuine peptide combination sold as a research-use-only reagent. This page is an informational dosing reference and an honest pointer to what Titan actually carries.

MK-677 · ibutamoren · oral GH secretagogue · research use only

MK-677 dosage, and the one thing that makes it different from every peptide on this site.

MK-677 (ibutamoren, formerly MK-0677, now LUM-201) is a growth-hormone secretagogue that acts at the ghrelin receptor — but unlike CJC-1295, ipamorelin or sermorelin it is not a peptide at all. It is a small, orally active molecule, which is why the research literature dosed it as a once-daily oral compound rather than a subcutaneous injection. This page reproduces the ~25 mg once-daily figure used in the studies, the roughly 24-hour half-life behind that cadence, and why an oral non-peptide has to be verified in a completely different way from a lyophilized peptide vial — framed as a research reference, not a human dosing protocol. Titan does not sell MK-677; the GH-axis compound Titan stocks is the injectable CJC-1295 + Ipamorelin blend.

In-stock GH-axis: CJC-1295 + Ipamorelin — $119.99 MK-677 vs Ipamorelin

The ~25 mg once-daily figure

The clinical work on ibutamoren converged on a single oral dose in the region of 25 mg per day. In the studies it raised 24-hour growth-hormone and IGF-1 concentrations in a dose-dependent way, and the 25 mg once-daily arm is the one most often cited. Because the effect is driven by a daily oral dose rather than a titration ladder, the research protocols were flat — one dose, taken consistently — not a stepped escalation like the incretin analogs.

How it compares to a peptide GHRP →

~24-hour half-life = once-daily

MK-677's elimination half-life is reported at roughly 24 hours, which is the property that lets a single daily dose sustain elevated GH pulses around the clock. That is a very different pharmacokinetic picture from the injectable secretagogues on this site, whose peptide half-lives are measured in minutes to a couple of hours and which are dosed accordingly. When a protocol compares oral MK-677 to an injectable blend, the dosing frequency is the first variable that separates them.

Compare the peptide half-lives →

Oral, not injectable — why there's no reconstitution

Because ibutamoren is an orally bioavailable small molecule, it does not ship as a lyophilized powder that a researcher reconstitutes with bacteriostatic water. There is no mg/mL math, no syringe draw, no BAC water. That convenience is exactly why some buyers reach for it — and exactly why its verification profile is different from a peptide vial you have to mix.

Formats, compared →

A COA for a non-peptide reads differently

You cannot verify MK-677 by a peptide sequence, because it has none. A meaningful certificate confirms small-molecule identity — the correct molecular mass by mass spectrometry and an HPLC main-peak purity against a stated target — for ibutamoren mesylate specifically. A vendor that hands you a 'peptide purity' sheet for a non-peptide is describing the wrong assay. Know which molecule class you are buying before you read the number.

How to read a COA →

The injectable GH-axis route Titan does stock

If the interest is the growth-hormone axis rather than MK-677 specifically, the compound Titan supplies is the CJC-1295 + Ipamorelin blend — a GHRH analog paired with a selective GHRP, dosed subcutaneously. It hits the axis by a different, injectable route and is a genuine peptide with a sequence you can verify. The comparison page lays the two approaches side by side.

See the in-stock blend →

Research-use framing

These figures describe doses used in human research on ibutamoren, reproduced here strictly as a laboratory reference for in-vitro and modelling work — not instructions for human use. MK-677 is an investigational compound; Titan does not sell it and supplies only research-use-only reagents, not for human or animal consumption. Nothing here is medical or dosing advice.

Research-use policy →

The detail, in plain terms

The MK-677 reference, in one table.

Ibutamoren's research profile is unusual on this site because it is not a peptide. These are the variables a researcher weighs when modelling it — reproduced as a reference, not a human protocol. Titan stocks the injectable CJC-1295 + Ipamorelin blend, not MK-677.

Compound: MK-677 / ibutamoren mesylate (MK-0677, LUM-201) — non-peptide ghrelin-receptor agonist.
Class: Orally active small molecule, not a peptide — no amino-acid sequence to verify.
Research dose: ≈25 mg once daily, oral (flat dose, not a titration ladder).
Half-life: ≈24 hours — the basis for once-daily administration.
Reconstitution: None — oral, no lyophilized powder, no BAC water or syringe.
Titan catalog: Not stocked. In-class option Titan sells: injectable CJC-1295 + Ipamorelin blend, $119.99.

Questions researchers ask

Before you order.

What is the research dosage of MK-677?: The human research on ibutamoren converged on roughly 25 mg once daily by mouth, a dose that raised 24-hour growth-hormone and IGF-1 concentrations in the studies. It was used as a flat daily dose rather than a stepped titration. These figures are reproduced as a laboratory research reference only and are not a human dosing protocol or medical advice.
What is MK-677's half-life?: MK-677's elimination half-life is reported at approximately 24 hours. That long duration of action is what allows a single daily dose to sustain elevated growth-hormone pulses, and it is the main pharmacokinetic difference from the injectable peptide secretagogues, whose half-lives are minutes to a couple of hours.
Is MK-677 a peptide?: No. Despite being grouped with 'peptides' in the research-compound community, MK-677 is an orally active small molecule that acts at the ghrelin receptor — it has no amino-acid sequence. That is why it is dosed orally instead of injected and why its certificate of analysis has to confirm small-molecule identity and purity rather than a peptide sequence.
Does Titan sell MK-677?: No. Titan does not stock MK-677. If the interest is the growth-hormone axis, the compound Titan supplies is the injectable CJC-1295 + Ipamorelin blend, a genuine peptide combination sold as a research-use-only reagent. This page is an informational dosing reference and an honest pointer to what Titan actually carries.
How should a MK-677 COA be verified?: Because MK-677 is not a peptide, verification means confirming small-molecule identity — the correct molecular mass by mass spectrometry and an HPLC main-peak purity against a stated target for ibutamoren mesylate. A generic 'peptide purity' sheet is describing the wrong assay for this molecule. Confirm the compound class first, then read the number.